Speakers

Ercem Atillasoy
Chief Regulatory & Safety Officer
AlloVir
Day One
Wednesday April 21
12:30 pm | Q&A/Discussion
11:40 am | Expedited Regulatory Pathways for Development & Licensure of Novel Anti-Infectives

Martin Everett
Chief Scientific Officer
AntaBio
Day One
Wednesday April 21
4:50 pm | Q&A/Discussion
4:00 pm | Pseudomonas Elastase (LasB) as a Therapeutic Target

Glenn Dale
Chief Development Officer
BioVersys
Day Two
Thursday April 22
12:30 pm | Q&A/Discussion
11:15 am | BV100 – a Novel Therapy for Antibiotic-Resistant Acinetobacter Infections

Kevin Outterson
Executive Director & Professor of Law
CARB-X & Boston University
Day One
Wednesday April 21
10:15 am | Q&A/Discussion
9:25 am | Surviving FDA Approval of your Antibiotic

Cara Cassino
Executive Vice President of R&D & Chief Medical Officer
ContraFect
Day Two
Thursday April 22
9:50 am | Q&A/Discussion
9:00 am | Direct Lytic Agents (DLA): New Medical Modalities for Life- Threatening, Drug-Resistant Infections

David Altarac
Chief Medical Officer
Entasis Therapeutics
Day Two
Thursday April 22
12:30 pm | Q&A/Discussion
12:05 pm | Targeted Therapy for Rare Pathogens: Challenges & Opportunities

Marc Navre
Chief Executive Officer & Chief Scientific Officer
Facile Therapeutics
Day One
Wednesday April 21
4:50 pm | Q&A/Discussion
4:25 pm | A De-Risked Small Molecule Anti-Toxin for the Treatment of C.difficile Infections

Dave Ousterout
Chief Scientific Officer
Locus Biosciences
Day One
Wednesday April 21
2:40 pm | Q&A/Discussion
1:50 pm | Clinical Experience with crPhage in Urinary Tract Infections

Silas Holland
Head of External Affairs (Interim) & Director of Global Public Policy
The AMR Action Fund & Merck
Day One
Wednesday April 21
10:15 am | Q&A/Discussion
9:00 am | AMR Action Fund: Strengthening & Accelerating Antibiotic Development

Mike Gordeev
Chief Scientific Officer
MicuRx Pharmaceuticals
Day Two
Thursday April 22
2:50 pm | Q&A/Discussion
2:25 pm | Novel Investigational Polymyxin MRX-8 with an Improved Safety & Efficacy against Key Gram-Negative Infections

John George
Co-Founder & Chief Scientific Officer
Oppilotech

Ed Siegwart
Director of Microbiology
Oppilotech

Jonathan Steckbeck
Founder, President & Chief Executive Officer
Peptilogics
Day One
Wednesday April 21
12:30 pm | Q&A/Discussion
12:05 pm | Differentiated Approach to Harnessing Novel Biologics & Overcome AMR

Jeanette Mucha
Chief Executive Officer & Co- Founder
SciBac
Day One
Wednesday April 21
2:40 pm | Q&A/Discussion
2:15 pm | Fighting Fire with Fire: Live Biotherapeutics for Pulmonary Infections

Angela Talley
Vice President of Clinical Development
Spero Therapeutics
Day Two
Thursday April 22
12:30 pm | Q&A/Discussion
11:40 am | Ensuring Anti-Infective Economic Sustainability by Targeting the Unmet Medical Need

David Powell
Chief Scientific Officer
Summit Therapeutics
Day Two
Thursday April 22
9:50 am | Q&A/Discussion
9:25 am | Building a Pipeline of New Mechanism Antibiotics that Drives Commercial Sustainability through Clinical Superiority

Nrusingh Mohapatra
Chief Scientific Officer
Techulon
Day Two
Thursday April 22
2:50 pm | Q&A/Discussion
2:00 pm | Obstacles for Discovery & Development of Narrow Spectrum Antimicrobials

Joseph DiMasi
Director of Economic Analysis
Tufts CSDD
Day One
Wednesday April 21
10:15 am | Q&A/Discussion
9:50 am | Trends in the Development & Approval of New Anti-infectives: Cycle Times, Success Rates & Expedited Regulatory Pathways

Silvia Caballero
Associate Director of Infectious Diseases
Vedanta Biosciences

Bernat Olle
Chief Executive Officer
Vedanta Biosciences

James Crowe
Director
Vanderbilt Vaccine Center

Mohammad Seyedsayamdost
Associate Professor of Chemistry & Molecular Biology
Princeton University

Peter Beyer
Senior Advisor and Team Lead
World Health Organization - WHO
Day One
Wednesday April 21